US5096830A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Preterm labor and membrane rupture test
Assignee: ASPEN DIAGNOSTICS Corp A CORP OF
•
Filing: 1988-09-15
•
Granted: 1992-03-17
•
Expires: 2008-09-15
Abstract
Abstract A method for determining increased risk of labor and fetal membrane rupture after week 20 of pregnancy comprises obtaining a secretion sample from the vaginal cavity; and determining the presence of a fetal restricted antigen in the sample. The sample can be removed from anywhere in the vaginal cavity, but is preferably removed from the posterior fornix or and/or cervical os. One fetal restricted antigen is fetal fibronectin. In one embodiment of this invention, the sample is contacted with an insoluble support to which anti-(fetal restricted antigen) antibody is adhered, and the fetal restricted antigen binding to the support is determined. Alternatively, the class of substances of which the fetal restricted antigen is a member is captured with a general binding antibody (such as anti-human fibronectin antibody), anti-(fetal restricted antigen) antibody (such as anti-fetal fibronectin antibody) is conjugated with the support, and binding with fetal restricted antigen is determined. Reagents and reagent kits are also included.
Inventors
- 👤 Andrew E. Senyei
- 👤 Nelson N. H. Teng
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 22:02
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/689; G01N33/74; G01N33/76; G01N2800/00; G01N2800/36; G01N2800/368; Y; Y10; Y10S; Y10S436/00; Y10S436/811; Y10S436/814
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
57 words
A method for determining signs and symptoms indicating risk of delivery comprising a) obtaining a secretion sample from the vaginal cavity or the cervical canal for a pregnant patient after week 20 of pregnancy; and b) determining the presence of fetal fibronectin in the sample, the presence of fetal fibronectin in the sample indicating risk of delivery.
Claim 2
Independent Claim
57 words
A method for determining signs and symptoms indicating risk of delivery comprising a) obtaining a secretion sample from the vaginal cavity or the cervical canal for a pregnant patient after week 20 of pregnancy; and b) determining the presence of fetal fibronectin in the sample, the presence of fetal fibronectin in the sample indicating risk of delivery.
Claim 3
Dependent Claim
14 words
The method of claim 1 wherein the sample is removed from the posterior fornix.
Claim 4
Dependent Claim
14 words
The method of claim 1 wherein the sample is obtained from the cervical os.
Claim 5
Dependent Claim
36 words
The method of claim 1 comprising the steps of a) contacting diluted sample with an anti-(fetal fibronectin) antibody for a time sufficient to permit antigen-antibody binding to occur; and b) determining the presence of said binding.
Claim 6
Dependent Claim
65 words
He method of claim 4 comprising the steps of a) contacting the sample with an insoluble support to which anti-(fetal fibronectin) antibody is adhered for a time sufficient to permit antigen-antibody binding to occur; b) contacting the insoluble support with an anti-fibronectin antibody for a time sufficient to permit antigen-antibody binding to occur; and c) determining the presence of anti-fibronectin antibody on the insoluble support.
Claim 7
Dependent Claim
14 words
The method of claim 5 wherein the anti-fibronectin antibody has a physically detectable label.
Claim 8
Dependent Claim
42 words
The method of claim 5 wherein the presence of anti-fibronectin antibody is determined by a) contacting the insoluble support with a labeled antibody which binds selectively with the anti-fibronectin antibody; and b) determining the presence of the label on the insoluble support.
Claim 9
Dependent Claim
66 words
He method of claim 1 comprising the steps of a) contacting the sample with an insoluble support to which anti-fibronectin antibody is adhered for a time sufficient to permit antigen-antibody binding to occur; b) contacting the insoluble support with an anti-(fetal fibronectin) antibody for a time sufficient to permit antigen-antibody binding to occur; and c) determining the presence of anti-(fetal fibronectin) antibody on the insoluble support.
Claim 10
Dependent Claim
15 words
The method of claim 8 wherein the anti-(fetal fibronectin) antibody has a physically detectable label.
Claim 11
Dependent Claim
44 words
The method of claim 8 wherein the presence of anti-(fetal fibronectin) antibody is determined by a) contacting the insoluble support with a labelled antibody which binds selectively with the anti-(fetal fibronectin) antibody; and b) determining the presence of the label on the insoluble support.
Claim 12
Dependent Claim
10 words
The method of claim 1 wherein said method determines labor.
Claim 13
Dependent Claim
12 words
The method of claim 1 wherein said method determines fetal membrane rupture.
Claim 14
Dependent Claim
13 words
The method of claim 1 wherein said pregnant patient is a preterm patient.
Claim 15
Dependent Claim
13 words
The method of claim 1 wherein said pregnant patient is a term patient.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-03-17 | 1995-09-16 | 1996-03-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-03-17 | 1999-09-16 | 2000-03-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-03-17 | 2003-09-16 | 2004-03-17 | $7700.00 | Window Closed / Lapsed |